North America Granulomatosis with Polyangiitis Treatment Market Report and Forecast 2025-2034

North America Granulomatosis with Polyangiitis Treatment Market Size

The global granulomatosis with polyangiitis treatment market is expected to grow at a CAGR of 4.90% during the forecast period of 2025-2034, with North America holding a significant market share. The market is driven by the increased clinical studies and research collaborations to advance treatment in granulomatosis with polyangiitis.

North America Granulomatosis with Polyangiitis Treatment Market Outlook

• The market share is influenced by the increased funding for rare disease research and the rising advancements in personalized medicine.

• The rising entry of high-quality biosimilars is likely to improve access to biologic therapies for a larger patient population and is poised to augment the North America granulomatosis with polyangiitis treatment market demand.

• One of the major market trends is the increased clinical trial activity and research collaborations focused on improving granulomatosis with polyangiitis treatments.

North America Granulomatosis with Polyangiitis Treatment Market Analysis

Granulomatosis with polyangiitis (GPA) is a rare disorder that causes inflammation of the blood vessels in the sinuses, nose, throat, kidneys, and lungs. The condition belongs to a group of blood vessel disorders called vasculitis. Immunosuppressive agents (such as cyclophosphamide, glucocorticoids, rituximab, and azathioprine) are prescribed in different combinations for treatment. The condition can be fatal if treatment is not given to the patient on time. Increased awareness and education initiatives are improving disease recognition and management, which impacts the treatment market for granulomatosis with polyangiitis significantly. Further, increased government initiatives and funding for rare disease research and the rising advancements in personalized therapeutic approaches are expected to propel the North America granulomatosis with polyangiitis treatment market growth.

The market is also impacted by the entry of biosimilars that are likely to enhance access to biologic therapies for a larger patient population. For instance, in July 2023, an Indian multinational pharmaceutical company Dr. Reddy's Laboratories Ltd., announced that the biologics license application (BLA) for its proposed rituximab biosimilar (DRL_RI) was accepted for a substantive review by the United States Food and Drug Administration (FDA). DRL_RI is being clinically developed as a biosimilar candidate of Roche’s Rituxan/MabThera (rituximab), which is approved for various indications including granulomatosis with polyangiitis. The rising introduction of high-quality biosimilars is poised to foster innovation and improvement in treatment options, which will ultimately impact the market value in coming years.

One of the major North America granulomatosis with polyangiitis treatment market trends is the increased clinical trial activity and research collaborations focused on GPA. In November 2023, a Phase 3 clinical trial of Tavneos (approved to treat granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)) revealed that patients who received Tavneos in combination with rituximab showed higher rates of sustained remission compared to similar patient group who received prednisone. The study was published in the journal Annals of the Rheumatic Diseases and funded by the original developer ChemoCentryx which is now acquired by Amgen Inc. Thus, the growth in the clinical studies is projected to expand the understanding of this rare condition and improve patient outcomes, which will bolster the market growth.

North America Granulomatosis with Polyangiitis Treatment Market Segmentation

The report offers a detailed analysis of the market based on the following segments:

Leading Companies in the North America Granulomatosis with Polyangiitis Treatment Market

The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

Roche Holding AG

F. Hoffmann-La Roche AG, a Swiss multinational holding healthcare company, has Mabthera/Rituxan (rituximab) drug which is FDA-approved for two rare forms of vasculitis including granulomatosis with polyangiitis.

GlaxoSmithKline plc (GSK)

This British multinational pharmaceutical and biotechnology company is a prominent market player and has received regulatory approval to market its drug candidate Nucala (mepolizumab) for targeted treatment of eosinophilic granulomatosis with polyangiitis (EGPA).

Pfizer Inc.

Pfizer Inc. is a key market player and actively invests in research and development of innovative treatments. Its RUXIENCE® (rituximab-pvvr) injection is indicated for granulomatosis with polyangiitis in adult patients in combination with glucocorticoids.

Sanofi

Sanofi is an innovative global healthcare company with a robust market presence. It is involved in the clinical development of new therapeutic treatments for rare diseases.

Other players in the market include Bristol Myers Squibb, Novartis AG, AbbVie Inc., Amgen Inc., Johnson & Johnson, and AstraZeneca plc.

Key Highlights of the Report

North America Granulomatosis with Polyangiitis Treatment Market Report Snapshots

North America Granulomatosis with Polyangiitis Treatment Market Size

North America Granulomatosis with Polyangiitis Treatment Market Analysis

North America Granulomatosis with Polyangiitis Treatment Companies